moistens and lubricates the ocular surface for prolonged relief of dry eye
symptoms associated with mechanical, environmental or visual stress such as
discomfort through wearing of contact lenses, air conditioning, wind, dryness of
air, or intensive work in front of a computer screen.
product consists solely of biological substances, most importantly sodium
hyaluronate 0.15% (HA) to stabilize the tear film. The ultrahigh molecular
weight HA used in Ocutears® has unique viscoelastic properties, combining the
therapeutic benefits of a 0.30% HA concentration (protection) with those of a
0.15% HA concentration (comfort). Ocutears® is intended to support corneal
healing as well as corneal re-epithelialization.
Ocutears® comes in an
easy-to-use preservative free multidose bottle that can be used for up to 6
months after the first opening.
markets Ocutears® in countries such as Poland, Lithuania, Georgia, Hungary,
Armenia, Latvia, Czech Republic - and now in Bulgaria.
In Europe, about 20%
of patients, who visit an ophthalmologist, suffer from dry eye symptoms.
Depending on age and gender, 5 to 35% of the population is affected. Women and
elderly people are more frequently concerned.
Founded in 1890,
Santen is a global company headquartered in Osaka, Japan. Santen researches,
develops and markets ophthalmic products for physicians worldwide. Among
prescription ophthalmic pharmaceuticals, Santen holds the top share within the
Japanese market and is one of the leading ophthalmic companies worldwide. Tokyo
Stock Exchange code 4536. For more information, visit www.santen.com.
Tel: + 33 6 65 54 60